Abstract
INTRODUCTION: New glucose-monitoring technologies have different cost-benefit profiles compared with traditional finger-prick tests, resulting in a preference-sensitive situation for patients. This study aimed to assess the relative value adults with diabetes assign to device attributes in two countries.
RESEARCH DESIGN AND METHODS: Adults with type 1 or 2 diabetes from the Netherlands (n=226) and Poland (n=261) completed an online discrete choice experiment. Respondents choose between hypothetical glucose monitors described using seven attributes: precision, effort to check, number of finger pricks required, risk of skin irritation, information provided, alarm function and out-of-pocket costs. Panel mixed logit models were used to determine attribute relative importance and to calculate expected uptake rates and willingness to pay (WTP).
RESULTS: The most important attribute for both countries was monthly out-of-pocket costs. Polish respondents were more likely than Dutch respondents to choose a glucose-monitoring device over a standard finger prick and had higher WTP for a device. Dutch respondents had higher WTP for device improvements in an effort to check and reduce the number of finger pricks a device requires.
CONCLUSION: Costs are the primary concern of patients in both countries when choosing a glucose monitor and would likely hamper real-world uptake. The costs-benefit profiles of such devices should be critically reviewed.
| Original language | English |
|---|---|
| Article number | A4 |
| Pages (from-to) | 1-11 |
| Number of pages | 11 |
| Journal | BMJ Open Diabetes Research & Care |
| Volume | 11 |
| Issue number | 1 |
| Early online date | 17 Jan 2023 |
| DOIs | |
| Publication status | Published - 2023 |
Bibliographical note
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Funding
This study formed part of the Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project. The PREFER project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115966). This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations.
| Funders | Funder number |
|---|---|
| Innovative Medicines Initiative | |
| European Federation of Pharmaceutical Industries and Associations | |
| Horizon 2020 Framework Programme | 115966 |
Keywords
- Adult
- Humans
- Patient Preference
- Netherlands/epidemiology
- Poland/epidemiology
- Diabetes Mellitus/epidemiology
- Glucose